What is Rhaeos?
Originating from the John A. Rogers Research Group at Northwestern University, Rhaeos is a specialized medical device company focused on the development of noninvasive, wireless wearable sensors. Its flagship technology, FlowSense, is specifically engineered to improve the management of hydrocephalus, a condition requiring precise and continuous monitoring. By leveraging advanced materials science and clinical research, Rhaeos occupies a unique niche at the intersection of deep-tech and patient-centric healthcare. The company's market position is bolstered by a robust network of public and private institutional support, reflecting its potential to disrupt traditional diagnostic and monitoring paradigms for chronic conditions.
How much funding has Rhaeos raised?
Rhaeos has raised a total of $12.7M across 2 funding rounds:
Angel/Seed
$2.2M
Series A
$10.5M
Angel/Seed (2021): $2.2M with participation from Lateral Capital, Creative Ventures, and Portal Innovations
Series A (2023): $10.5M led by Steele Foundation for Hope, Lateral Capital, and Creative Ventures
Key Investors in Rhaeos
Lateral Capital
Lateral Capital is a mission-driven venture fund that partners with visionary entrepreneurs to build essential digital infrastructure, offering flexible and patient capital from seed to growth stages.
Creative Ventures
Creative Ventures is a method-driven venture capital firm that invests in scalable technologies designed to solve critical global-scale challenges while mitigating R&D risks.
Portal Innovations
Portal Innovations is a venture development engine and life sciences firm focused on early-stage biotech and medtech, providing capital, lab space, and strategic support to accelerate breakthroughs.
What's next for Rhaeos?
With the recent influx of capital, Rhaeos is expected to prioritize the clinical validation and commercialization of its FlowSense platform. The strategic focus will likely shift toward scaling manufacturing capabilities and expanding clinical trial footprints to meet the rigorous demands of the medtech industry. As the company moves deeper into its clinical-stage lifecycle, the emphasis will remain on securing regulatory approvals and establishing the necessary infrastructure to support widespread adoption. Investors are closely monitoring the firm's ability to translate its academic research roots into a scalable, market-ready product that provides tangible improvements in patient outcomes for those suffering from difficult-to-treat neurological conditions.
See full Rhaeos company page
